Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade
@article{Millan2005AnxiolyticPO, title={Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade}, author={Mark J. Millan and Mauricette Brocco and Alain P. Gobert and Anne Dekeyne}, journal={Psychopharmacology}, year={2005}, volume={177}, pages={448-458} }
RationaleThe novel antidepressant agent, agomelatine, behaves as an agonist at melatonin receptors and as an antagonist at serotonin (5-HT)2C receptors.ObjectivesTo determine whether, by virtue of its antagonist properties at 5-HT2C receptors, agomelatine elicits anxiolytic properties in rats.MethodsEmploying a combined neurochemical and behavioural approach, actions of agomelatine were compared to those of melatonin, the selective 5-HT2C receptor antagonist, SB243,213, and the benzodiazepine…
245 Citations
The melatonergic agonist and clinically active antidepressant, agomelatine, is a neutral antagonist at 5-HT(2C) receptors.
- Biology, PsychologyThe international journal of neuropsychopharmacology
- 2011
Agomelatine behaves as a neutral antagonist at constitutively active h5-HT 2C(INI)Rs and native, cortical 5-HT2CRs and is of interest to determine whether the neutral antagonist properties of agomel atine are related to its favourable clinical profile of antidepressant properties with few side-effects and no discontinuation syndrome.
Beyond the monoaminergic hypothesis: Agomelatine, a new antidepressant with an innovative mechanism of action
- Psychology, BiologyThe world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry
- 2009
Interestingly, agomelatine demonstrated antidepressant efficacy not only in patients with a moderate depressive episode but also in a more severe depressed subpopulation of patients, and the treatment effect increased with the severity of the disease.
S32006, a novel 5-HT2C receptor antagonist displaying broad-based antidepressant and anxiolytic properties in rodent models
- Biology, PsychologyPsychopharmacology
- 2008
In vitro and in vivo, the novel benzourea derivative, S32006 is a potent 5-HT2C receptor antagonist, and possesses antidepressant and anxiolytic properties in diverse rodent models.
Agomelatine suppresses locomotor hyperactivity in olfactory bulbectomised rats: a comparison to melatonin and to the 5-HT(2c) antagonist, S32006.
- Psychology, BiologyEuropean journal of pharmacology
- 2012
Influence of the novel antidepressant and melatonin agonist/serotonin2C receptor antagonist, agomelatine, on the rat sleep–wake cycle architecture
- Psychology, BiologyPsychopharmacology
- 2009
Agomelatine possesses a distinctive EEG profile compared with melatonin, ramelteon, and S32006, possibly reflecting co-joint agonist and antagonist properties at MT1/MT2 and 5-HT2C receptors, respectively.
Agomelatine: mechanism of action and pharmacological profile in relation to antidepressant properties
- BiologyBritish journal of pharmacology
- 2014
The present review focuses on the pharmacological properties of this novel antidepressant, strikingly different from that of conventional classes of antidepressants, and opens perspectives towards a better understanding of the physiopathological bases underlying depression.
Anxiolytic effects of the melatonin MT2 receptor partial agonist UCM765: Comparison with melatonin and diazepam
- Biology, PsychologyProgress in Neuro-Psychopharmacology and Biological Psychiatry
- 2012
Serotonin-2C receptors in the basolateral nucleus of the amygdala mediate the anxiogenic effect of acute imipramine and fluoxetine administration.
- Psychology, BiologyThe international journal of neuropsychopharmacology
- 2012
The findings indicate that 5-HT2CRs in BLA are selectively involved in the regulation of defensive behaviours associated with generalized anxiety, but not panic, and provide the first direct evidence that activation of BLA 5- HT2 CRs accounts for the short-term aversive effect of antidepressants.
Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies.
- Psychology, BiologyTherapie
- 2005
There is evidence that stimulation of regionally discrete populations of 5-HT2C receptors is effective in certain behavioural models of antidepressant activity, and promotes neurogenesis in the hippocampus, which underpin interest in 5- HT2C receptor blockade as a strategy for treating depressive and anxious states.
17β-Estradiol augments the neuroprotective effect of agomelatine in depressive- and anxiety-like behaviors in ovariectomized rats
- Biology, PsychologyPsychopharmacology
- 2020
The combined treatment of E2 and Ago is evaluated as a treatment of choice for depression, anxiety, and sleep disturbances associated with menopause and augmented the neuroprotective effect of Ago in OVX rats via its anti-inflammatory and neurotrophic effects.
References
SHOWING 1-10 OF 74 REFERENCES
Anxiolytic Properties of the Selective, Non-peptidergic CRF1 Antagonists, CP154,526 and DMP695: A Comparison to Other Classes of Anxiolytic Agent
- Biology, PsychologyNeuropsychopharmacology
- 2001
Anxiolytic-like properties of melatonin receptor agonists in mice: involvement of mt1 and/or MT2 receptors in the regulation of emotional responsiveness
- Biology, PsychologyNeuropharmacology
- 2000
Preclinical evaluation of the reinforcing and discriminative stimulus effects of agomelatine (S-20098), a melatonin agonist
- Psychology, BiologyPsychopharmacology
- 1998
Results suggest that agomelatine would not produce diazepam-like intoxication in humans, nor would it likely be subject to abuse.
The Novel Melatonin Agonist Agomelatine (S20098) Is an Antagonist at 5-Hydroxytryptamine2C Receptors, Blockade of Which Enhances the Activity of Frontocortical Dopaminergic and Adrenergic Pathways
- Biology, ChemistryJournal of Pharmacology and Experimental Therapeutics
- 2003
In contrast to melatonin, agomelatine behaves as an antagonist at 5- HT2B and 5-HT2C receptors: blockade of the latter reinforces frontocortical adrenergic and dopaminergic transmission.
SB-243213; a selective 5-HT2C receptor inverse agonist with improved anxiolytic profile: lack of tolerance and withdrawal anxiety
- Psychology, BiologyNeuropharmacology
- 2001
Melatonin analogues as agonists and antagonists in the circadian system and other brain areas.
- BiologyEuropean journal of pharmacology
- 1996
Agomelatine(S 20098) antagonizes the penile erections induced by the stimulation of 5-HT2C receptors in Wistar rats
- Biology, MedicinePsychopharmacology
- 2003
Data suggested that the reported effects were not due to the stimulation of melatonin receptors and that, contrary to melatonin, agomelatine exerted 5-HT2C receptor antagonist properties in addition to its agonist activity atmelatonin receptors.
A Comparative Study of the Effects of Selective and Non-Selective 5-HT2 Receptor Subtype Antagonists in Rat and Mouse Models of Anxiety
- Biology, PsychologyNeuropharmacology
- 1997
Evidence for accelerated desensitisation of 5-HT2C receptors following combined treatment with fluoxetine and the 5-HT1A receptor antagonist, WAY 100,635, in the rat
- Psychology, BiologyNeuropharmacology
- 2000
Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT2C antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study
- Psychology, MedicineInternational clinical psychopharmacology
- 2002
It is demonstrated that agomelatine is efficient in the treatment of major depressive disorder and that 25 mg is the target dose.